NCT01149850View on ClinicalTrials.gov

Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 28, 2010

Primary Completion Date

December 8, 2023

Study Completion Date

December 8, 2023

Conditions
Giant Cell GlioblastomaGlioblastomaGliosarcoma
Interventions
BIOLOGICAL

bevacizumab

Given IV

DRUG

temozolomide

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

immunohistochemistry staining method

Correlative studies

GENETIC

microarray analysis

Correlative studies

GENETIC

DNA methylation analysis

Correlative studies

Trial Locations (3)

90027

Kaiser Foundation Hospital, Los Angeles

90095

University of California, Los Angeles, Los Angeles

92120

Kaiser Permanente at San Diego, San Diego

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER